

# Breast Cancer Oncology Enrollment Form



Fax Referral To: 1-855-297-1270

Phone: 1-888-280-1190

Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

NCPDP: 4026325

## Six Simple Steps to Submitting a Referral

### 1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender:  Male  Female

Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_

Preferred Contact Methods:  Phone (to primary # provided below)  Text (to cell # provided below)  Email (to email provided below)

**Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.**

Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_\_

Email: \_\_\_\_\_ Last Four of SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_

Parent/Caregiver/Legal Guardian Name (Last, First): \_\_\_\_\_ Relationship to patient: \_\_\_\_\_

### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_ State License #: \_\_\_\_\_

NPI #: \_\_\_\_\_ DEA #: \_\_\_\_\_ Group or Hospital: \_\_\_\_\_

Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_ Contact's Phone: \_\_\_\_\_

### 3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

### 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: \_\_\_\_\_ Ship to:  Patient  Office  Other: \_\_\_\_\_

#### Diagnosis (ICD-10):

C50 Malignant neoplasm of breast  Code: \_\_\_\_\_ Description \_\_\_\_\_

Code: \_\_\_\_\_ Description \_\_\_\_\_  Code: \_\_\_\_\_ Description \_\_\_\_\_

**Patient Clinical Information:** Allergies: \_\_\_\_\_ Weight: \_\_\_lb/kg Height: \_\_\_in/cm BSA: \_\_\_\_\_m<sup>2</sup>

### 5 PRESCRIPTION INFORMATION

#### Medications:

- |   |  |   |
|---|--|---|
| <input type="checkbox"/> Afinitor (everolimus)                                  | <input type="checkbox"/> Herzuma (trastuzumab-pkrb)                | <input type="checkbox"/> Paclitaxel   |
| <input type="checkbox"/> Arimidex (anastrozole)                                 | <input type="checkbox"/> Ibrance (palbociclib)                     | <input type="checkbox"/> Perjeta (pertuzumab)                               |
| <input type="checkbox"/> Aromasin (exemestane)                                  | <input type="checkbox"/> Ixempra (ixabepilone)                     | <input type="checkbox"/> Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) |
| <input type="checkbox"/> Capecitabine   | <input type="checkbox"/> Kadcyla (ado-trastuzumab emtansine)       | <input type="checkbox"/> Piqray (alpelisib)                                 |
| <input type="checkbox"/> Cisplatin  | <input type="checkbox"/> Kanjinti (trastuzumab-anns)               | <input type="checkbox"/> Talzenna (talazoparib)                             |
| <input type="checkbox"/> Enhertu (fam-trastuzumab deruxtecan-nxki)              | <input type="checkbox"/> Kisqali (ribociclib)                      | <input type="checkbox"/> Trazimera (trastuzumab-qyyp)                       |
| <input type="checkbox"/> Fareston (toremifene citrate)                          | <input type="checkbox"/> Kisqali Femara (ribociclib and letrozole) | <input type="checkbox"/> Tykerb (lapatinib)                                 |
| <input type="checkbox"/> Faslodex (fulvestrant)                                 | <input type="checkbox"/> Margenza (margetuximab-cmkb)              | <input type="checkbox"/> Verzenio (abemaciclib)                             |
| <input type="checkbox"/> Femara (letrozole)                                     | <input type="checkbox"/> Nerlynx (neratinib)                       | <input type="checkbox"/> Xeloda (capecitabine)                              |
| <input type="checkbox"/> Fluorouracil   | <input type="checkbox"/> Ogivri (trastuzumab-dkst)                 | <input type="checkbox"/> Zoladex (goserelin acetate implant)                |
| <input type="checkbox"/> Herceptin (trastuzumab)                                | <input type="checkbox"/> Ontruzant (trastuzumab-dttb)              | <input type="checkbox"/> Other _____  |
| <input type="checkbox"/> Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) | <input type="checkbox"/> Onxol (paclitaxel)                        |   |

PRESCRIPTIONS	DRUG NAME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
RX 1	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 2	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

Patient is interested in patient support programs

**STAMP SIGNATURE NOT ALLOWED**

Ancillary supplies and kits provided as needed for administration

### 6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

<p>"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute</p> <p>Prescriber's Signature: _____ Date: _____</p>	<p>May Substitute / Product Selection Permitted / Substitution Permissible</p> <p>Prescriber's Signature: _____ Date: _____</p>
--	---

**CA, MA, NC & PR:** Interchange is mandated unless Prescriber writes the words "No Substitution" \_\_\_\_\_ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.